WA
BMRN icon

Wealth Alliance’s BioMarin Pharmaceuticals BMRN Stock Holding History

Wealth Alliance’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-2,185
Closed -$211K – 522
2023
Q4 		$211K Sell
2,185
-249
-10% -$22K 0.03% 476
2023
Q3 		$215K Buy
+2,434
New +$217K 0.03% 443
2023
Q1 		– Sell
-2,112
Closed -$219K – 506
2022
Q4 		$219K Sell
2,112
-250
-11% -$23.5K 0.04% 444
2022
Q3 		$200K Buy
+2,362
New +$210K 0.04% 424
2022
Q1 		– Sell
-3,497
Closed -$309K – 446
2021
Q4 		$309K Buy
3,497
+194
+6% +$16K 0.06% 322
2021
Q3 		$255K Buy
3,303
+171
+5% +$13.5K 0.06% 345
2021
Q2 		$261K Buy
3,132
+72
+2% +$5.71K 0.06% 359
2021
Q1 		$231K Buy
3,060
+615
+25% +$50.2K 0.06% 350
2020
Q4 		$214K Buy
+2,445
New +$194K 0.06% 353
2020
Q3 		– Sell
-1,750
Closed -$216K – 316
2020
Q2 		$216K Buy
+1,750
New +$174K 0.09% 276

Other funds holding BMRN

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Wealth Alliance's BMRN Position: Q1 2024 in Review

Wealth Alliance sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2024, closing a stake of 2,185 shares — an estimated $211K sold.

Wealth Alliance first reported a position in BMRN in Q2 2020 and held it in 10 quarters. The position peaked at $309K in Q4 2021. 560 funds tracked by Wall St. Rank hold BMRN as of Q1 2024.

  • Wealth Alliance reported no remaining BioMarin Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Wealth Alliance sold 2,185 BioMarin Pharmaceuticals shares in Q1 2024, an estimated $211K.
  • Wealth Alliance first reported a position in BioMarin Pharmaceuticals in Q2 2020 and held it in 10 quarters.
  • Wealth Alliance's BioMarin Pharmaceuticals position peaked at $309K in Q4 2021.
  • 560 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2024.

Based on Wealth Alliance's 13F filing for Q1 2024, filed 10 May 2024.